Crescent Biopharma, Inc

CBIONASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

27.8M

on 2026-06-30, from 1.02M on 2024-03-31 10-Q ↗

Earlier counts are adjusted for the 1-for-63 reverse split; each bar's tip shows the count as filed.

a raise that quarter, at its price

Newest

$500.0M

S-3 of 2026-07-01. 1 prospectus supplement filed under it since. S-3 ↗

$200.0M

Jefferies, agreement of 2026-07-01. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

The 10-Q filed 2026-07-30 is not read yet.

Cash

9.4 quarters

$171.6M on 2026-06-30 ÷ $18.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-07-14	Public offering incl. 0.53M pre-funded	8,620,690	$14.50	$125.0M	424B5 ↗
2025-06-18	Private placement	not read	not read	$200.0M	8-K ↗

Also on file: a 1-for-100 reverse split, 2025-05-14 8-K ↗